Hanmi Science Reports 24% Operating Profit Growth in Q1 2026 and Strengthens Shareholder Returns

Consolidated Q1 2026 revenue: KRW 353.7bn (+6.5% YoY), operating profit: KRW 33.6bn (+24% YoY), net income: KRW 42.3bn.
In Dec 2025, announced 'Value-Up Plan': targeting minimum shareholder return rate of 30% annually from 2025-2030, including minimum dividend, share buybacks, and RSU for employees.
Key subsidiary Hanmi Pharm's obesity/diabetes drug efpeglenatide received fast-track designation from MFDS in Nov 2025 and filed for approval in Dec 2025. Signed license agreement for encequidar with Gilead (Sep 2025).
Equity method gains from associates reached KRW 21.9bn (up from KRW 19.9bn in prior quarter), contributing to consolidated earnings.
Financial soundness: debt ratio 39.33%, cash and cash equivalents KRW 115.4bn.

ADVERTISEMENT (250px+)